ProfileGDS5678 / 1417032_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 90% 86% 89% 86% 85% 80% 87% 87% 87% 85% 87% 88% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4737886
GSM967853U87-EV human glioblastoma xenograft - Control 27.1772890
GSM967854U87-EV human glioblastoma xenograft - Control 36.5995886
GSM967855U87-EV human glioblastoma xenograft - Control 47.1242989
GSM967856U87-EV human glioblastoma xenograft - Control 56.5402386
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0938185
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5047480
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6634187
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5806387
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6803387
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4027585
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8117287
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8672388
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7167287